Patients with BRAF mutant melanoma and receiving targeted therapy will often show a dramatic reduction in melanoma burden, followed by recurrent melanoma growth from residual disease (or persister cells) (Marine et al., 2020; Shen et al., 2020b). This evidence concerns the gene BRAF and melanoma.